|
Canada-11200-ADVERTISING DIRECT MAIL selskapets Kataloger
|
Firma Nyheter:
- Arcturus Therapeutics | A Commercial mRNA Medicines Company
Arcturus Therapeutics is a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases
- Arcturus Therapeutics - Wikipedia
Arcturus Therapeutics Holdings Inc is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases
- Arcturus Therapeutics Holdings Inc. (ARCT) - Yahoo Finance
Find the latest Arcturus Therapeutics Holdings Inc (ARCT) stock quote, history, news and other vital information to help you with your stock trading and investing
- Why Arcturus Therapeutics Holdings Inc. ’s (ARCT) Stock Is Up 5. 20%
Arcturus Therapeutics Holdings Inc ’s (ARCT) price is currently up 4 55% so far this month During the month of June, Arcturus Therapeutics Holdings Inc ’s stock price has reached a high of $13 620 and a low of $11 830 Over the last year, Arcturus Therapeutics Holdings Inc has hit prices as high as $27 540 and as low as $8 040
- Press Releases - Arcturus Therapeutics, Inc.
Arcturus Therapeutics, Inc (Nasdaq: ARCT) provides frequent updates covering developments and breakthroughs on our mRNA medicines and vaccines See our latest press releases
- Arcturus Therapeutics to Host Key Opinion Leader (KOL . . . - BioSpace
Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics Arcturus’ pipeline includes RNA therapeutic candidates to potentially treat OTC deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza
- Arcturus Therapeutics Holdings Inc. (ARCT)
Arcturus Therapeutics Holdings Inc engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases Its technology platforms includes
- Arcturus Pipeline of mRNA Medicines and Vaccines - Arcturus Therapeutics
In a wholly owned program, Arcturus is developing a messenger RNA (mRNA) medicine to treat ornithine transcarbamylase deficiency, a life-threatening genetic disease that affects over 10,000 people worldwide OTC is a key urea cycle enzyme in liver cells that helps eliminate ammonia from the body
- Meet The Team | Arcturus Therapeutics
Backed by a management team with extensive experience in the discovery and development of RNA medicines, Arcturus is on the forefront of research and development of RNA chemistry and delivery technologies
- Arcturus Therapeutics Announces First Quarter 2025 Financial Update and . . .
Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics
|
|